Galderma’s Nemluvio® (Nemolizumab) EU Approval for Atopic Dermatitis and Prurigo Nodularis

Galderma’s Nemluvio® (Nemolizumab) EU Approval for Atopic Dermatitis and Prurigo Nodularis Galderma announced that the European Commission has granted approval for Nemluvio® (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio, a…









